285 related articles for article (PubMed ID: 30922248)
1. First-in-class immune-modulating small molecule Icaritin in advanced hepatocellular carcinoma: preliminary results of safety, durable survival and immune biomarkers.
Fan Y; Li S; Ding X; Yue J; Jiang J; Zhao H; Hao R; Qiu W; Liu K; Li Y; Wang S; Zheng L; Ye B; Meng K; Xu B
BMC Cancer; 2019 Mar; 19(1):279. PubMed ID: 30922248
[TBL] [Abstract][Full Text] [Related]
2. Icaritin-induced immunomodulatory efficacy in advanced hepatitis B virus-related hepatocellular carcinoma: Immunodynamic biomarkers and overall survival.
Qin SK; Li Q; Ming Xu J; Liang J; Cheng Y; Fan Y; Jiang J; Ye H; Tao H; Li L; Zheng L; Wei Z; Li S; Meng K; Ye B; Sun Y
Cancer Sci; 2020 Nov; 111(11):4218-4231. PubMed ID: 32889778
[TBL] [Abstract][Full Text] [Related]
3. Icaritin Induces Anti-tumor Immune Responses in Hepatocellular Carcinoma by Inhibiting Splenic Myeloid-Derived Suppressor Cell Generation.
Tao H; Liu M; Wang Y; Luo S; Xu Y; Ye B; Zheng L; Meng K; Li L
Front Immunol; 2021; 12():609295. PubMed ID: 33717093
[TBL] [Abstract][Full Text] [Related]
4. Nivolumab in patients with advanced hepatocellular carcinoma and Child-Pugh class B cirrhosis: Safety and clinical outcomes in a retrospective case series.
Kambhampati S; Bauer KE; Bracci PM; Keenan BP; Behr SC; Gordan JD; Kelley RK
Cancer; 2019 Sep; 125(18):3234-3241. PubMed ID: 31154669
[TBL] [Abstract][Full Text] [Related]
5. A phase II trial of second-line axitinib following prior antiangiogenic therapy in advanced hepatocellular carcinoma.
McNamara MG; Le LW; Horgan AM; Aspinall A; Burak KW; Dhani N; Chen E; Sinaei M; Lo G; Kim TK; Rogalla P; Bathe OF; Knox JJ
Cancer; 2015 May; 121(10):1620-7. PubMed ID: 25565269
[TBL] [Abstract][Full Text] [Related]
6. Phase 2 study of lenvatinib in patients with advanced hepatocellular carcinoma.
Ikeda K; Kudo M; Kawazoe S; Osaki Y; Ikeda M; Okusaka T; Tamai T; Suzuki T; Hisai T; Hayato S; Okita K; Kumada H
J Gastroenterol; 2017 Apr; 52(4):512-519. PubMed ID: 27704266
[TBL] [Abstract][Full Text] [Related]
7. HATT: a phase IV, single-arm, open-label study of sorafenib in Taiwanese patients with advanced hepatocellular carcinoma.
Lin SM; Lu SN; Chen PT; Jeng LB; Chen SC; Hu CT; Yang SS; Le Berre MA; Liu X; Mitchell DY; Prins K; Grevel J; Peña CA; Meinhardt G
Hepatol Int; 2017 Mar; 11(2):199-208. PubMed ID: 27909950
[TBL] [Abstract][Full Text] [Related]
8. New insights into the anticancer therapeutic potential of icaritin and its synthetic derivatives.
Reyes-Hernández OD; Figueroa-González G; Quintas-Granados LI; Hernández-Parra H; Peña-Corona SI; Cortés H; Kipchakbayeva A; Mukazhanova Z; Habtemariam S; Leyva-Gómez G; Büsselberg D; Sharifi-Rad J
Drug Dev Res; 2024 Apr; 85(2):e22175. PubMed ID: 38567708
[TBL] [Abstract][Full Text] [Related]
9. Single-cell immune signature for detecting early-stage HCC and early assessing anti-PD-1 immunotherapy efficacy.
Shi J; Liu J; Tu X; Li B; Tong Z; Wang T; Zheng Y; Shi H; Zeng X; Chen W; Yin W; Fang W
J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35101942
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Cheng AL; Kang YK; Chen Z; Tsao CJ; Qin S; Kim JS; Luo R; Feng J; Ye S; Yang TS; Xu J; Sun Y; Liang H; Liu J; Wang J; Tak WY; Pan H; Burock K; Zou J; Voliotis D; Guan Z
Lancet Oncol; 2009 Jan; 10(1):25-34. PubMed ID: 19095497
[TBL] [Abstract][Full Text] [Related]
11. Identification of sphingosine kinase 1 (SphK1) as a primary target of icaritin in hepatocellular carcinoma cells.
Lu PH; Chen MB; Liu YY; Wu MH; Li WT; Wei MX; Liu CY; Qin SK
Oncotarget; 2017 Apr; 8(14):22800-22810. PubMed ID: 28206952
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial.
Vilgrain V; Pereira H; Assenat E; Guiu B; Ilonca AD; Pageaux GP; Sibert A; Bouattour M; Lebtahi R; Allaham W; Barraud H; Laurent V; Mathias E; Bronowicki JP; Tasu JP; Perdrisot R; Silvain C; Gerolami R; Mundler O; Seitz JF; Vidal V; Aubé C; Oberti F; Couturier O; Brenot-Rossi I; Raoul JL; Sarran A; Costentin C; Itti E; Luciani A; Adam R; Lewin M; Samuel D; Ronot M; Dinut A; Castera L; Chatellier G;
Lancet Oncol; 2017 Dec; 18(12):1624-1636. PubMed ID: 29107679
[TBL] [Abstract][Full Text] [Related]
13. Nanomedicine-boosting icaritin-based immunotherapy of advanced hepatocellular carcinoma.
Lu Y; Gao Y; Yang H; Hu Y; Li X
Mil Med Res; 2022 Dec; 9(1):69. PubMed ID: 36503490
[TBL] [Abstract][Full Text] [Related]
14. Emerging immune checkpoint inhibitors for the treatment of hepatocellular carcinoma.
Chan LL; Chan SL
Expert Opin Emerg Drugs; 2021 Mar; 26(1):39-52. PubMed ID: 33724135
[TBL] [Abstract][Full Text] [Related]
15. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial.
Zhu AX; Finn RS; Edeline J; Cattan S; Ogasawara S; Palmer D; Verslype C; Zagonel V; Fartoux L; Vogel A; Sarker D; Verset G; Chan SL; Knox J; Daniele B; Webber AL; Ebbinghaus SW; Ma J; Siegel AB; Cheng AL; Kudo M;
Lancet Oncol; 2018 Jul; 19(7):940-952. PubMed ID: 29875066
[TBL] [Abstract][Full Text] [Related]
16. Randomized Phase II Study of the X-linked Inhibitor of Apoptosis (XIAP) Antisense AEG35156 in Combination With Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC).
Lee FA; Zee BC; Cheung FY; Kwong P; Chiang CL; Leung KC; Siu SW; Lee C; Lai M; Kwok C; Chong M; Jolivet J; Tung S
Am J Clin Oncol; 2016 Dec; 39(6):609-613. PubMed ID: 24977690
[TBL] [Abstract][Full Text] [Related]
17. Phase I/II study of temsirolimus for patients with unresectable Hepatocellular Carcinoma (HCC)- a correlative study to explore potential biomarkers for response.
Yeo W; Chan SL; Mo FK; Chu CM; Hui JW; Tong JH; Chan AW; Koh J; Hui EP; Loong H; Lee K; Li L; Ma B; To KF; Yu SC
BMC Cancer; 2015 May; 15():395. PubMed ID: 25962426
[TBL] [Abstract][Full Text] [Related]
18. A phase I/II trial of the oral antiangiogenic agent TSU-68 in patients with advanced hepatocellular carcinoma.
Kanai F; Yoshida H; Tateishi R; Sato S; Kawabe T; Obi S; Kondo Y; Taniguchi M; Tagawa K; Ikeda M; Morizane C; Okusaka T; Arioka H; Shiina S; Omata M
Cancer Chemother Pharmacol; 2011 Feb; 67(2):315-24. PubMed ID: 20390419
[TBL] [Abstract][Full Text] [Related]
19. Sorafenib in advanced hepatocellular carcinoma: hypertension as a potential surrogate marker for efficacy.
Estfan B; Byrne M; Kim R
Am J Clin Oncol; 2013 Aug; 36(4):319-24. PubMed ID: 22547010
[TBL] [Abstract][Full Text] [Related]
20. Phase I study of PF-03446962, a fully human monoclonal antibody against activin receptor-like kinase-1, in patients with hepatocellular carcinoma.
Simonelli M; Zucali P; Santoro A; Thomas MB; de Braud FG; Borghaei H; Berlin J; Denlinger CS; Noberasco C; Rimassa L; Kim TY; English PA; Abbattista A; Gallo Stampino C; Carpentieri M; Williams JA
Ann Oncol; 2016 Sep; 27(9):1782-7. PubMed ID: 27329247
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
